Scarica l'app Stockscreener
291.01
2.07%
-6.16
Dopo l'orario di chiusura:
291.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$297.17
Aprire:
$296.08
Volume 24 ore:
370.28K
Relative Volume:
1.00
Capitalizzazione di mercato:
$7.79B
Reddito:
$2.59B
Utile/perdita netta:
$168.80M
Rapporto P/E:
47.90
EPS:
6.0748
Flusso di cassa netto:
$357.20M
1 W Prestazione:
-4.53%
1M Prestazione:
+14.43%
6M Prestazione:
-7.62%
1 anno Prestazione:
+26.24%
Intervallo 1D:
$290.21
$298.57
Intervallo di 1 settimana:
$290.21
$312.27
Portata 52W:
$222.80
$343.12
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Nome
Bio Rad Laboratories Inc
Settore
Industria
Telefono
(510) 724-7000
Indirizzo
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
291.01 | 7.95B | 2.59B | 168.80M | 357.20M | 6.0748 |
ABT
Abbott Laboratories
|
89.17 | 158.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
308.84 | 120.38B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.25 | 105.25B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
48.34 | 72.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.98 | 50.41B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-07 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-04-03 | Downgrade | Citigroup | Buy → Neutral |
| 2023-12-07 | Iniziato | UBS | Buy |
| 2023-06-16 | Iniziato | Wells Fargo | Overweight |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-01-28 | Reiterato | Citigroup | Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2018-10-17 | Iniziato | Goldman | Buy |
| 2018-09-20 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Downgrade | CL King | Buy → Neutral |
| 2017-07-13 | Iniziato | Wells Fargo | Outperform |
| 2017-06-28 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Iniziato | Deutsche Bank | Hold |
| 2016-10-13 | Iniziato | CL King | Buy |
| 2015-05-06 | Reiterato | Jefferies | Buy |
| 2009-12-18 | Iniziato | Maxim Group | Buy |
| 2009-11-06 | Iniziato | Jefferies & Co | Buy |
| 2009-07-17 | Iniziato | Soleil | Buy |
| 2007-09-26 | Iniziato | Banc of America Sec | Buy |
| 2007-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
Mostra tutto
Bio Rad Laboratories Inc Borsa (BIO) Ultime notizie
Bio-Rad Receives MicroVal Validation for Two EZ-Check Listeria Testing Kits - Quality Assurance & Food Safety
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Limited Upside Amid a Competitive Landscape - DirectorsTalk Interviews
BIO - Finviz
Bio-Rad receives MicroVal validation for EZ-Check™ Listeria testing kits - News-Medical
Elliott builds big stake in life-science firm Bio-Rad Labs, WSJ reports - MSN
Bio Rad Laboratories Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
In Vitro Diagnostic (IVD) Quality Control Market Overview, Key - openPR.com
(BIO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
BioRad Listeria Test Kits Receive MicroVal Certification - Food Safety Magazine
Bio-Rad receives microVal validation for EZ-CheckTM Listeria spp. and EZ-Check Listeria monocytogenes Testing Kits - Cambridge Network
Bio-Rad (BIO) Q1 2026 Earnings Transcript - AOL.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a Tight Market with Strategic Growth Potential - DirectorsTalk Interviews
Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching - 富途牛牛
Bio-Rad Is a Strategic Investor in Sartorius, With Around $5B Stake -- WSJ - Moomoo
A Look at Bio-Rad Laboratories Inc (BIO) After 4.2% Gain -- GF V - GuruFocus
[144] BIO-RAD LABORATORIES, INC. SEC Filing - Stock Titan
Bio-Rad Laboratories stock (US09062X1037): sector focus as Elliott stake and price gains keep NYSE l - AD HOC NEWS
Form 144 BIO-RAD LABORATORIES For: 28 May By Investing.com - Investing.com South Africa
Bio-Rad’s valuation may be hard to justify as revenue growth lags industry forecasts. Optimistic investor sentiment could reverse if growth fails to improve, potentially putting pressure on the stock. - Moomoo
Is Elliott’s Sartorius Push Altering The Investment Case For Bio-Rad Laboratories (BIO)? - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating the Medical Device Terrain with a 3.22% Upside - DirectorsTalk Interviews
Is It Time To Reassess Bio-Rad Laboratories (BIO) After Its Recent 16% Weekly Surge? - Sahm
Bio-Rad Laboratories, Inc. Class B Trade Ideas — BOATS:BIO.B - TradingView
(BIO) Risk Channels and Responsive Allocation - Stock Traders Daily
Elliott Targets Bio-Rad After 70% Stock Collapse - GuruFocus
Dow Jones Top Company Headlines at 1 AM ET: Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad - Moomoo
Research Alert: CFRA Maintains Sell Rating On Shares Of Bio-rad Laboratories Inc. - Moomoo
Bio-Rad outlines 2026 currency-neutral revenue growth of -3% to +0.5% amid Middle East disruption - MSN
Bio-Rad cuts 2026 outlook as Amgen lifts forecast - MSN
Bio Rad Laboratories Stock Surges 11% on Reports of Activist Elliott Investment Management Stake - TIKR.com
BIO: Digital PCR growth and quality controls drive performance amid regional and market headwinds - TradingView
BIO: Digital PCR and quality controls drive growth, with margin expansion and efficiency in focus - TradingView
How Investors Are Reacting To Bio-Rad Laboratories (BIO) As RBC Sees Margin Upside Under New Leadership - Sahm
Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday - Sahm
Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories - Sahm
Bio-Rad Laboratories (BIO) Stock Soars 13% on Elliott Management Investment News - GuruFocus
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 13.8% Rally? GF Value Says Undervalued - GuruFocus
Why Elliott sees hidden billions inside Bio-Rad Laboratories - MSN
Bio-Rad (BIO) Sees Significant Stock Surge - GuruFocus
Bio-Rad rallies 13.9% as activist stake speculation lifts shares - Quiver Quantitative
BIO Stock Pops As Elliott Targets Turnaround And RBC Sees Upside - timothysykes.com
BIO Stock Jumps As Elliott Activist Stake Meets Bullish RBC Call - StocksToTrade
Nvidia Earnings Could Decide Whether the AI Trade Still Holds - Investing.com
Research Alert: Bio-rad Laboratories Rallies On Wsj Report Of Elliott Management Stake - Moomoo
Bio-Rad (BIO) Sees 10.5% Surge in Stock Value - GuruFocus
Why Is Bio-Rad Laboratories Stock Trending Now - Kalkine Media
Elliott Builds Big Position In Bio-Rad | The Wall Street Journalnewspaper - Magzter
Macy's, Dominion Energy, Bio-Rad Laboratories - TradingView
Bio Rad Laboratories Inc Azioni (BIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):